Zach McLellan, Tara Hansen, Tom Tyler, and David Dahan discuss notable presentations and data releases from the 2020 ASCO meeting.
Topics covered in this episode include:
• TIGIT + PD-L1: Tiragolumab w/ Tecentriq for NSCLC (:45)
• Phase III ADAURA trial update: adjuvant Tagrisso for NSCLC (5:10)
• JAVELIN Bladder 100 - Bavencio as maintenance therapy in urothelial carcinoma (10:00)
• Final OS data from TIVO-3 unlikely to lead to US approval for Tivopath in RCC (14:27)
• Phase II Pevonedistat-2001 trial: Pevonedistat for AML/MDS(19:05)
• Phase I/II EVOLVE study: orva-cel for mutliple myeloma (25:05)
• CodeBreak 100 - AMG510 update (32:54)
• ADP-A2M4 SPEAR T cells in solid tumors (38:45)
To learn more about Datamonitor Healthcare, Biomedtracker, and other offerings from Pharma Intelligence, visit:
pharmaintelligence.informa.com/
